Abstract
Background and ImportanceTreatment landscape for relapsed/refractory Multiple Myeloma (RRMM) has changed significantly due to the availability and good results of new drugs such as immunotherapy agents.Phase I clinical trials (CTs)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have